Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix LLC Completes Patient Enrollment in the ELEVATE IDE Clinical Study

Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

VEITH 2017 Presentation: Status of the LEOPARD Trial: Comparing the AFX Endologix Graft to other Standard EVAR Endografts

Endologix Appoints John Onopchenko as Chief Operating Officer

Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix® EndoVascular Aneurysm Sealing System